Regeneron Pharmaceuticals Inc (REGN)vsZevra Therapeutics Inc. (ZVRA)
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
ZVRA
Zevra Therapeutics Inc.
$9.13
-0.22%
HEALTHCARE · Cap: $537.21M
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 13371% more annual revenue ($14.34B vs $106.47M). ZVRA leads profitability with a 78.2% profit margin vs 31.4%. REGN appears more attractively valued with a PEG of 1.56. ZVRA earns a higher WallStSmart Score of 62/100 (C+).
REGN
Buy58
out of 100
Grade: C
ZVRA
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Margin of Safety
+7.6%
Fair Value
$9.18
Current Price
$9.13
$0.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Attractively priced relative to earnings
Every $100 of equity generates 86 in profit
Keeps 78 of every $100 in revenue as profit
Strong operational efficiency at 27.3%
Areas to Watch
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
1.8% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 78.2% and operating margin at 27.3%.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : ZVRA
The primary concerns for ZVRA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ZVRA carries more volatility with a beta of 0.94 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ZVRA scores higher overall (62/100 vs 58/100), backed by strong 78.2% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?